1,720,986 research outputs found
Preoperative and postoperative evaluation of prostate-specific antigen in localized prostatic cancer treated by radical prostatectomy
No full textPreoperative prostate-specific antigen (PSA) values were determined in 73 patients with clinically localized prostatic cancer and candidates for a radical procedure. Correlation of preoperative PSA with a final pathological stage was attempted. Only in 44.8% of our 22 patients with organ-confined disease was the PSA value within the normal range; in 17.3% of cases PSA values were higher than 20 ng/ml. 18.2% of the patients with locally advanced disease showed normal PSA values, while 45.5% had concentrations above 20 ng/ml. In the case of lymph node involvement, PSA values were normal in 22.7% of the cases. Our data indicate that no strict relationship can be suggested between PSA and the final pathological stage and grading of the tumor in patients who underwent radical prostatectomy
La dinamica minzionale nel reflusso vescicoureterale. L’ effetto di sottrazione pressoria nel distretto cervicouretrale.
No full text
Going Beyond Counting First Authors in Author Co-citation Analysis
Full text linkThe present study examines one of the fundamental aspects of author co-citation analysis (ACA) - the way co-citation
counts are defined. Co-citation counting provides the data on which all subsequent statistical analyses and mappings
are based, and we compare ACA results based on two different types of co-citation counting - the traditional type that
only counts the first one among a cited work's authors on the one hand and a non-traditional type that takes into
account the first 5 authors of a cited work on the other hand. Results indicate that the picture produced through this non-traditional author co-citation counting contains more coherent author groups and is therefore considerably clearer. However, this picture represents fewer specialties in the research field being studied than that produced through the traditional first-author co-citation counting when the same number of top-ranked authors is selected and analyzed. Reasons for these effects are discussed
Valutazione della fosfatasi acida e prostatica nel siero e nel midollo con metodo radioimmunologico in pazienti con neoplasia prostatica.
No full textRadiotherapy and concomitant Docetaxel in very high risk prostatic cancer our esperience in the first 30 patients
No full textHigh-risk prostate cancer patients (cT3, N1, PSA ≥ 20 ng/ml and/or Gleason score ≥8) have a 5-year biochemical failure rate after surgery or radiation of 50% or higher. In this group of patients hormonal therapy (HT) is currently the best systemic treatment option in association with radiotherapy (RT). Due to the heterogeneity of prostate cancer (CaP) cells and attempt to improve the outcome with RT, weekly chemotherapy (CHT) during RT, in localized, high-risk CaP is being explored. Docetaxel has demonstrated a significant anti-tumor effect and impact on survival in hormone refractory CaP and can increase the sensitivity of tumor cells to radiation injury.
Patients and Methods: From 2005 to 2010, 30 very high risk patients (pts) were treated with high dose of RT and concomitant Docetaxel. Of these, 17/30 (Group 1) underwent surgery before RT and they were all characterized by pathological advanced disease; 13/30 (Group 2) underwent radical RT and they all presented a clinically advanced disease. Group 1 median age was 65 years (range 57-80); the pathological Gleason Score (pGS) was 8 in 4 and 9 in 13 pts; the pTNM was pT2c in 2, pT3a in 3, pT3b in 10 and pT4 in 2 pts. Nodes were positive in 3 pts; surgical positive margins were found in 6 cases. PSA median level, at diagnosis, was 18 (range 4.25-56.3) and PSA prior to RT was 0.65 ng/ml (range 0.01-4.22); RT median dose, was 70 Gy (range 66-76).
Group 2 median age was 73 years (range 65-81); the bioptic GS was 7 in 1, 8 in 4, 9 in 7 pts and 10 in 1 case; cTNM was T3 in 8 and T2 in 5 pts; PSA median level at diagnosis was 9,3 (range 5,27-71,3) and PSA prior to RT was 0,51 ng/ml (0,05-3,83); RT median dose was 80 Gy (range 76-80).
Docetaxel was administered in a standard weekly dose (30 mg for pts with m2=2). Median cycles of CHT was 7 (range 2-8). All pts began HT before and during RT and continued the treatment for 2 years after RT.
Results: The median follow up was of 36 months (8-60). Only 6 pts, after a median period of 14 months, presented a recurrent disease (locally or/and to the bones). Median PSA at 3 months after RT was 0.04 (0.01-1.1) ng/ml, and at the last follow up was 0.04 (0.01-1.9). As to the toxicity: gastrointestinal grade I was complained by 18/30 and urological grade I by 12/30 pts. Two patients had to stop CHT infusion after two cycles for systemic toxicity.
Conclusion: These preliminary data confirm the feasibility and the tolerability of weekly Docetaxel in combination with RT in men with high risk of disease progression. No pts suffered a performance status worsening during the scheduled treatment. At the median follow up of 36 months, only 20% of pts were relapsed. An increase number of recruited pts and a longer follow up are necessary to confirm the validity of these preliminary results
- …
